Vinva Investment Management Ltd Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Vinva Investment Management Ltd grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 45.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 3,779 shares of the biopharmaceutical company’s stock after purchasing an additional 1,182 shares during the period. Vinva Investment Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $2,655,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $26,000. Truvestments Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 15 shares during the last quarter. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $28,000. Finally, Larson Financial Group LLC lifted its stake in shares of Regeneron Pharmaceuticals by 127.3% in the 3rd quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 28 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 1.1 %

Shares of NASDAQ:REGN opened at $672.36 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The business’s fifty day simple moving average is $691.62 and its 200-day simple moving average is $822.93. The company has a market capitalization of $73.51 billion, a PE ratio of 17.56, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the business posted $11.86 EPS. The business’s revenue was up 10.3% compared to the same quarter last year. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Sanford C. Bernstein decreased their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Citigroup decreased their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Finally, Truist Financial decreased their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.